Research & Development World

  • R&D World Home
  • Topics
    • Aerospace
    • Automotive
    • Biotech
    • Careers
    • Chemistry
    • Environment
    • Energy
    • Life Science
    • Material Science
    • R&D Management
    • Physics
  • Technology
    • 3D Printing
    • A.I./Robotics
    • Software
    • Battery Technology
    • Controlled Environments
      • Cleanrooms
      • Graphene
      • Lasers
      • Regulations/Standards
      • Sensors
    • Imaging
    • Nanotechnology
    • Scientific Computing
      • Big Data
      • HPC/Supercomputing
      • Informatics
      • Security
    • Semiconductors
  • R&D Market Pulse
  • R&D 100
    • Call for Nominations: The 2025 R&D 100 Awards
    • R&D 100 Awards Event
    • R&D 100 Submissions
    • Winner Archive
    • Explore the 2024 R&D 100 award winners and finalists
  • Resources
    • Research Reports
    • Digital Issues
    • Educational Assets
    • R&D Index
    • Subscribe
    • Video
    • Webinars
  • Global Funding Forecast
  • Top Labs
  • Advertise
  • SUBSCRIBE

NICE Approves Stelara for Crohn’s Disease

By NICE | June 19, 2017

Following NICE recommendations, patients with Crohn’s disease will have routine NHS access to drug ustekinumab, which offers a new way of treating the condition.

Ustekinumab (also called Stelara, manufactured by Janssen) will be available for patients with moderate to severe Crohn’s disease.

It is recommended by NICE as an option for treating the disease in adults who have had little or no response, or an intolerance to existing therapies.

Crohn’s disease is an inflammatory bowel disease, and can affect any part of the digestive system. Symptoms can include stomach cramps, diarrhoea and fatigue. It is a chronic condition which means that is it lifelong.

Ustekinumab works in a different way to existing treatments and is already recommended by NICE to treat psoriasis and psoriatic arthritis.

It is an innovative human monoclonal antibody treatment which binds to specific proteins on cells, known as IL-21 and IL-23. This stops the production of cytokines which cause the inflammatory response inside the body.

Professor Carole Longson, director of the health technology evaluation centre at NICE, said: “We are delighted to be able to recommend ustekinumab for routine NHS use. Crohn’s disease can have a debilitating impact on a person’s quality of life, from self-esteem through to experiencing regular relapses.

“Ustekinumab provides a convenient and viable option for patients with Crohn’s. It is a new way of treating the disease compared to conventional treatment, and can be used where other options have already been tried and stopped working.”

There is an estimated 132,049 people with Crohn’s in England and Wales, and just under 28,000 are estimated to be eligible for this treatment.

The committee heard that the disease follows an unpredictable pattern of remission and relapse, significantly impacting patients’ everyday lives. The evidence showed ustekinumab improved quality of life and is well tolerated amongst patients.

Sarah Berry, Health Policy & Public Affairs Officer from Crohn’s and Colitis UK, said: “We are delighted that NICE has recommended ustekinumab as a treatment option for adults with Crohn’s disease and has listened to and valued the evidence from patients through the appraisal process. The impact of uncontrolled symptoms of Crohn’s disease can be profoundly debilitating and current treatment options simply do not work for everyone.  This ruling gives access to a desperately needed additional treatment to those who may otherwise have been condemned to living with unmanageable disease progression with devastating impact on their quality of life.  We now look forward to people being able to access this treatment option as soon as possible”.

The final draft guidance is now with consultees, who have the opportunity to appeal against it until Friday 30 June. Once NICE recommends a treatment ‘as an option’ in final guidance, the NHS must make sure it is available within three months (unless otherwise specified) of its date of publication.

This draft guidance does not mean that people currently taking ustekinumab will stop receiving it.

Related Articles Read More >

5 R&D developments to keep an eye on this week: Solar crash and Trump’s energy pivot meets Musk’s rebellion
Mayo Clinic develops AI tool that can spot 9 dementia types with a single scan
Google DeepMind’s AlphaGenome AI predicts how non-coding DNA can drive disease
Top 10 drugs by patent volume: How biologics build ‘platform empires’ while small molecule create ‘patent thickets’
rd newsletter
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest info on technologies, trends, and strategies in Research & Development.
RD 25 Power Index

R&D World Digital Issues

Fall 2024 issue

Browse the most current issue of R&D World and back issues in an easy to use high quality format. Clip, share and download with the leading R&D magazine today.

Research & Development World
  • Subscribe to R&D World Magazine
  • Enews Sign Up
  • Contact Us
  • About Us
  • Drug Discovery & Development
  • Pharmaceutical Processing
  • Global Funding Forecast

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search R&D World

  • R&D World Home
  • Topics
    • Aerospace
    • Automotive
    • Biotech
    • Careers
    • Chemistry
    • Environment
    • Energy
    • Life Science
    • Material Science
    • R&D Management
    • Physics
  • Technology
    • 3D Printing
    • A.I./Robotics
    • Software
    • Battery Technology
    • Controlled Environments
      • Cleanrooms
      • Graphene
      • Lasers
      • Regulations/Standards
      • Sensors
    • Imaging
    • Nanotechnology
    • Scientific Computing
      • Big Data
      • HPC/Supercomputing
      • Informatics
      • Security
    • Semiconductors
  • R&D Market Pulse
  • R&D 100
    • Call for Nominations: The 2025 R&D 100 Awards
    • R&D 100 Awards Event
    • R&D 100 Submissions
    • Winner Archive
    • Explore the 2024 R&D 100 award winners and finalists
  • Resources
    • Research Reports
    • Digital Issues
    • Educational Assets
    • R&D Index
    • Subscribe
    • Video
    • Webinars
  • Global Funding Forecast
  • Top Labs
  • Advertise
  • SUBSCRIBE